- Direct factor Xa inhibitor rivaroxaban2009 | Faculty of Medicine in Hradec Králové
- Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study2022 | Faculty of Medicine in Hradec Králové
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study2008 | First Faculty of Medicine
- Perpendicular Magnetic Anisotropy of Tb in Tb(xA)/Fe(40A) (x=5-30)1997 | Faculty of Mathematics and Physics
- News in therapy and prevention of venous thromboembolism +12008 | Faculty of Medicine in Hradec Králové
- News in therapy and prevention of venous thromboembolism2008 | First Faculty of Medicine
- Dravidian and Altaic ‘to break, to beat, to crush, to rub’ (Ta. kavi - Mo. xabir- / xa)2005 | Publication without faculty affiliation
- Decrease of soluble P-selectin and inhibition both, activated factor XA and trombin after i.v.enoxaparin during PCIPublication without faculty affiliation
- Dravidian and Altaic 'to break, to beat, to crush, to rub' (Ta. kavi - Mo. xabir- / xa)2005 | Faculty of Mathematics and Physics
- Rivaroxaban - a newly marketed antithrombotic agent2009 | First Faculty of Medicine
- Apixaban, a new oral antithrombotic agent - Review of marketing authorisation studies2012 | Second Faculty of Medicine
- Characterization of innovative Pt-ceria catalysts for PEMFC by means of ex-situ and operando X-Ray Absorption Spectroscopy2022 | Faculty of Mathematics and Physics
- Electronic structure and spectral properties of heavy actinides Pu, Am, Cm and Bk2010 | Faculty of Mathematics and Physics
- Local geometry around B atoms in B/Si(111) from polarized x-ray absorption spectroscopyPublication without faculty affiliation
- Apixabans2011 | First Faculty of Medicine, Third Faculty of Medicine
- Exploring the Antitumor Potential of Copper Complexes Based on Ester Derivatives of Bis(pyrazol-1-yl)acetate LigandsPublication without faculty affiliation
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study +12008 | Faculty of Medicine in Hradec Králové
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study2008 | Second Faculty of Medicine
- Anticoagulation 20132013 | Faculty of Medicine in Hradec Králové
- Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin2014 | Publication without faculty affiliation
- Novel anticoagulants in prevention of cardioembolic stroke in patiens with non-valvular atrial fibrillation2013 | First Faculty of Medicine
- Randomized, Double-Blind, Dose-Ranging Sudy of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. The SEPIA-PCI Trial2007 | First Faculty of Medicine
- Randomized, Double-Blind, Dose-Ranging Sudy of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. The SEPIA-PCI Trial2007 | Faculty of Physical Education and Sport
- Reduced Thrombin Generation and Soluble P-selectin After Intravenous Enoxaparin During PCI2011 | First Faculty of Medicine
- Prevention of cardioembolic stroke2012 | First Faculty of Medicine
- Edoxaban - medication profile2013 | Publication without faculty affiliation
- Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage in Anticoagulated Patients2020 | Faculty of Medicine in Hradec Králové
- Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction Results From the ATLAS ACS-2-TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51)2013 | Third Faculty of Medicine
